PAHC Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of Phibro Animal Health Corp(PAHC) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Phibro Animal Health Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2026Q1
2025-11-05
After Hours
0.59
0.73
+23.73
345.44M
363.90M
+5.35
+4.59
+10.16
FY2025Q4
2025-08-27
After Hours
0.52
0.57
+9.62
362.24M
378.70M
+4.54
+19.44
+18.62
FY2025Q3
2025-05-07
After Hours
0.52
0.63
+21.15
352.41M
347.80M
-1.31
+14.75
+26.87
FY2025Q2
2025-02-05
After Hours
0.41
0.54
+31.71
316.53M
309.26M
-2.30
+9.88
+9.97
FY2024Q4
2024-08-28
After Hours
0.34
0.41
+20.59
260.49M
273.20M
+4.88
+3.17
-6.11
FY2024Q3
2024-05-08
-
0.29
0.31
+6.90
253.65M
263.20M
+3.77
+2.44
+8.59
FY2024Q2
2024-02-07
-
0.27
0.33
+22.22
240.94M
249.90M
+3.72
-1.39
+4.71
FY2024Q1
2023-11-08
-
0.21
0.14
-33.33
242.04M
231.30M
-4.44
-0.50
-15.95
FY2023Q4
2023-08-30
-
0.40
0.38
-5.00
256.13M
255.00M
-0.44
+0.14
-12.10
-
2023-05-03
-
0.33
0.29
-12.12
-
-
-
-0.13
-11.40
PAHC Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Phibro Animal Health Corp reported performance for FY2026Q1, announced on 2025-11-05. The company achieved an EPS of 0.73, compared to analyst estimates of 0.59 by 23.73% . Revenue for the quarter reached 363.90M compared to expectations of 345.44M by 5.35% .
The stock price reacted with a 4.59% one-day change and a 10.16% five-day change following the earnings release. These movements reflect market reaction in Phibro Animal Health Corp growth trajectory and strategic initiatives.
PAHC Earnings Forecast
Looking ahead, Phibro Animal Health Corp(PAHC) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q2 project quarter revenue of 355.64M and an EPS of 0.67.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Upward by 0.46%, while EPS estimates have been Revise Upward by 3.9%. For the upcoming Q2 2026, revenue estimates have been adjusted Revise Downward by -0.9% . These revisions correlate with a 4.26% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Phibro Animal Health Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between PAHC's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2026
Revise Upward
+0.46%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
+3.9%
In Past 3 Month
Revenue Estimates for Q2 2026
Revise Downward
-0.9%
In Past 3 Month
Stock Price
Go Up
+4.26%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2026:1.47B
--
EPS Estimate-Annual FY 2026:2.74
—
Stock Price40.67
PAHC Revenue and EPS Performance: A Historical Perspective
Phibro Animal Health Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2026Q1 (2025-11-05,After Hours):
EPS: 0.73 (Actual) vs.0.59 (Estimate) (23.73%)
Revenue: 363.90M (Actual) vs. 345.44M (Estimate) (5.35%)
Price Reaction:4.59%(1-Day), 10.16%(5-Day)
FY2025Q4 (2025-08-27,After Hours):
EPS: 0.57 (Actual) vs.0.52 (Estimate) (9.62%)
Revenue: 378.70M (Actual) vs. 362.24M (Estimate) (4.54%)
Price Reaction:19.44%(1-Day), 18.62%(5-Day)
FY2025Q3 (2025-05-07,After Hours):
EPS: 0.63 (Actual) vs.0.52 (Estimate) (21.15%)
Revenue: 347.80M (Actual) vs. 352.41M (Estimate) (-1.31%)
Price Reaction:14.75%(1-Day), 26.87%(5-Day)
Earnings Reaction
The chart below shows how PAHC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PAHC sees a -6.89% change in stock price 10 days leading up to the earnings, and a +4.51% change 10 days following the report. On the earnings day itself, the stock moves by -0.08%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 4.59% on the day following the earnings release and then changed by 0.56% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of PAHC's latest earnings report for FY2026Q1?
PAHC reported its FY2026Q1 earnings on 2025-11-05, showcasing a revenue of 363.90M against an estimate of 345.44M, resulting in a 5.35% surprise. The EPS was 0.73, surpassing the expected 0.59 by 23.73% . The stock experienced a 4.59% price change on the earnings day and a 10.16% change over the next five days, reflecting market reactions to the results.
How did PAHC's stock price react after the FY2026Q1 earnings release?
Following PAHC's FY2026Q1 earnings announcement on 2025-11-05, the stock price moved by 4.59% on the day of the release. Over the subsequent five days, it saw a 10.16% change. Historically, PAHC's stock price tends to shift by an average of -6.89% in the 10 days leading up to earnings and +4.51% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for PAHC for 2026/Q2?
For 2026/Q2, analysts estimate PAHC’s annual revenue to reach 355.64M, while the EPS is projected at 0.67. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.46% and EPS estimates Revise Downward by -0.9% over the past three months, indicating analyst expectation in the company’s performance.
How does PAHC's stock price correlate with earnings forecast revisions?
The correlation between PAHC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.46%, while EPS estimates moved Revise Downward by -0.9% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from PAHC's next earnings report?
Based on historical trends, PAHC's stock price typically moves by -6.89% in the 10 days before its earnings and +4.51% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.67 and revenue of 355.64M.
What is the sentiment in Phibro Animal Health Corp (PAHC) Q1 2026 Earnings Call Summary?
The earnings call reveals strong financial performance, with notable growth in net sales and adjusted EBITDA, especially in the Animal Health segment. The optimistic guidance and strategic initiatives, such as the Phibro Forward Initiative and Zoetis portfolio contributions, support a positive outlook. Despite some uncertainties in growth sustainability, management's confidence in demand and profitability, along with strategic expansions into companion animals, suggest a favorable market reaction. The decision not to update guidance reflects caution rather than negative sentiment, aligning with a positive stock price outlook.
